Nedaplatin‑based chemotherapy regimens combined with concurrent radiotherapy as first‑line treatment for stage II‑III esophageal squamous cell carcinoma

  • Authors:
    • Huiping Zhu
    • Xiaolin Ge
    • Yufeng Lu
    • Yun Zuo
    • Qin Qin
    • Xinchen Sun
    • Min Yang
  • View Affiliations

  • Published online on: October 10, 2018     https://doi.org/10.3892/ol.2018.9564
  • Pages: 594-602
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Concurrent chemoradiotherapy (CCRT) is an effective first‑line treatment for esophageal squamous cell carcinoma (ESCC). The present study aimed to compare clinical outcomes between three nedaplatin‑based regimens for CCRT of ESCC. Patients with stage II‑III thoracic ESCC in China between January 2012 and May 2016 were included. Patients received esophageal ultrasonography prior to treatment. Chemotherapy was as follows: i) 100 mg/m2 nedaplatin intravenously on day 1 and 70 mg/m2 tegafur‑gimeracil‑oteracil potassium (S‑1) orally twice daily for 2 weeks; ii) 50 mg/m2 nedaplatin intravenously on days 1 and 2 and 35 mg/m2 docetaxel intravenously on days 1 and 8; or iii) 60 mg/m2 nedaplatin intravenously on days 1 and 2. Intensity‑modulated radiotherapy was used to administer a total dose of 60‑66 Gy (1.8‑2.0 Gy per fraction) to the primary tumor and 45‑50 Gy to the subclinical region. A total of 70 patients were enrolled (median age, 66 years; range, 50‑81 years). T4 disease was identified in 45 (64.3%) patients. All patients completed radiotherapy and received ≥2 chemotherapy cycles. Estimated 1‑, 2‑ and 3‑year overall survival (OS) rates were 82.9, 53.9 and 31.4%, respectively. OS and progression‑free survival were similar between the three treatment groups. Grade 3/4 hematological toxicities were observed in 35 (50%) patients. The incidence of serious treatment‑associated toxicities was numerically highest for the nedaplatin/docetaxel combination. Patients with thoracic ESCC had good clinical outcomes following CCRT. With similar survival rates and disease responses yet lower hematological toxicities, nedaplatin/S‑1 and single‑agent nedaplatin may be preferable to nedaplatin/docetaxel. Poor control of distant metastasis may be a disadvantage of single‑agent chemotherapy use in CCRT, and a further study with larger cohorts is required to confirm this.
View Figures
View References

Related Articles

Journal Cover

January-2019
Volume 17 Issue 1

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Zhu H, Ge X, Lu Y, Zuo Y, Qin Q, Sun X and Yang M: Nedaplatin‑based chemotherapy regimens combined with concurrent radiotherapy as first‑line treatment for stage II‑III esophageal squamous cell carcinoma. Oncol Lett 17: 594-602, 2019
APA
Zhu, H., Ge, X., Lu, Y., Zuo, Y., Qin, Q., Sun, X., & Yang, M. (2019). Nedaplatin‑based chemotherapy regimens combined with concurrent radiotherapy as first‑line treatment for stage II‑III esophageal squamous cell carcinoma. Oncology Letters, 17, 594-602. https://doi.org/10.3892/ol.2018.9564
MLA
Zhu, H., Ge, X., Lu, Y., Zuo, Y., Qin, Q., Sun, X., Yang, M."Nedaplatin‑based chemotherapy regimens combined with concurrent radiotherapy as first‑line treatment for stage II‑III esophageal squamous cell carcinoma". Oncology Letters 17.1 (2019): 594-602.
Chicago
Zhu, H., Ge, X., Lu, Y., Zuo, Y., Qin, Q., Sun, X., Yang, M."Nedaplatin‑based chemotherapy regimens combined with concurrent radiotherapy as first‑line treatment for stage II‑III esophageal squamous cell carcinoma". Oncology Letters 17, no. 1 (2019): 594-602. https://doi.org/10.3892/ol.2018.9564